IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v7y2016i1d10.1038_ncomms11138.html
   My bibliography  Save this article

Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft

Author

Listed:
  • Muhammad M. Mohiuddin

    (Cardiothoracic Surgery Research Program, NHLBI, NIH)

  • Avneesh K. Singh

    (Cardiothoracic Surgery Research Program, NHLBI, NIH)

  • Philip C. Corcoran

    (Cardiothoracic Surgery Research Program, NHLBI, NIH)

  • Marvin L. Thomas III

    (ORS, NIH)

  • Tannia Clark

    (NICHD/NIH)

  • Billeta G. Lewis

    (ORS, NIH)

  • Robert F. Hoyt

    (Leidos Biomedical Research, Inc.)

  • Michael Eckhaus

    (ORS, NIH)

  • Richard N. Pierson III

    (University of Maryland Medical Center)

  • Aaron J. Belli

    (MassBiologics, University of Massachusetts Medical School)

  • Eckhard Wolf

    (Ludwig Maximilian University)

  • Nikolai Klymiuk

    (Ludwig Maximilian University)

  • Carol Phelps

    (Revivicor Inc.)

  • Keith A. Reimann

    (MassBiologics, University of Massachusetts Medical School)

  • David Ayares

    (Revivicor Inc.)

  • Keith A. Horvath

    (Cardiothoracic Surgery Research Program, NHLBI, NIH)

Abstract

Preventing xenograft rejection is one of the greatest challenges of transplantation medicine. Here, we describe a reproducible, long-term survival of cardiac xenografts from alpha 1-3 galactosyltransferase gene knockout pigs, which express human complement regulatory protein CD46 and human thrombomodulin (GTKO.hCD46.hTBM), that were transplanted into baboons. Our immunomodulatory drug regimen includes induction with anti-thymocyte globulin and αCD20 antibody, followed by maintenance with mycophenolate mofetil and an intensively dosed αCD40 (2C10R4) antibody. Median (298 days) and longest (945 days) graft survival in five consecutive recipients using this regimen is significantly prolonged over our recently established survival benchmarks (180 and 500 days, respectively). Remarkably, the reduction of αCD40 antibody dose on day 100 or after 1 year resulted in recrudescence of anti-pig antibody and graft failure. In conclusion, genetic modifications (GTKO.hCD46.hTBM) combined with the treatment regimen tested here consistently prevent humoral rejection and systemic coagulation pathway dysregulation, sustaining long-term cardiac xenograft survival beyond 900 days.

Suggested Citation

  • Muhammad M. Mohiuddin & Avneesh K. Singh & Philip C. Corcoran & Marvin L. Thomas III & Tannia Clark & Billeta G. Lewis & Robert F. Hoyt & Michael Eckhaus & Richard N. Pierson III & Aaron J. Belli & Ec, 2016. "Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft," Nature Communications, Nature, vol. 7(1), pages 1-10, September.
    • Handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11138
    DOI: 10.1038/ncomms11138
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms11138
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms11138?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11138. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.